BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 37329341)

  • 21. Delayed post-operative haemorrhage after carmustine wafer implantation: a case series from two UK centres.
    Shah RS; Homapour B; Casselden E; Barr JG; Grundy PL; Brydon HL
    Br J Neurosurg; 2014 Aug; 28(4):488-94. PubMed ID: 24313309
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase I trial of surgery, Gliadel wafer implantation, and immediate postoperative carboplatin in combination with radiation therapy for primary anaplastic astrocytoma or glioblastoma multiforme.
    Limentani SA; Asher A; Heafner M; Kim JW; Fraser R
    J Neurooncol; 2005 May; 72(3):241-4. PubMed ID: 15937647
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic factors and survival in a prospective cohort of patients with high-grade glioma treated with carmustine wafers or temozolomide on an intention-to-treat basis.
    Catalán-Uribarrena G; Bilbao-Barandica G; Pomposo-Gaztelu I; Undabeitia-Huertas J; Ruiz de Gopegui-Ruiz E; Galbarriatu-Gutiérrez L; Canales-Llantada M; Aurrecoechea-Obieta J; Igartua-Azkune A; Carbayo-Lozano G
    Acta Neurochir (Wien); 2012 Feb; 154(2):211-22; discussion 222. PubMed ID: 22002506
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor resection with carmustine wafer placement as salvage therapy after local failure of radiosurgery for brain metastasis.
    Mu F; Lucas JT; Watts JM; Johnson AJ; Daniel Bourland J; Laxton AW; Chan MD; Tatter SB
    J Clin Neurosci; 2015 Mar; 22(3):561-5. PubMed ID: 25560387
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy.
    Affronti ML; Heery CR; Herndon JE; Rich JN; Reardon DA; Desjardins A; Vredenburgh JJ; Friedman AH; Bigner DD; Friedman HS
    Cancer; 2009 Aug; 115(15):3501-11. PubMed ID: 19514083
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospective study of carmustine wafers in combination with 6-month metronomic temozolomide and radiation therapy in newly diagnosed glioblastoma: preliminary results.
    Salmaggi A; Milanesi I; Silvani A; Gaviani P; Marchetti M; Fariselli L; Solero CL; Maccagnano C; Casali C; Guzzetti S; Pollo B; Ciusani E; Dimeco F
    J Neurosurg; 2013 Apr; 118(4):821-9. PubMed ID: 23350777
    [TBL] [Abstract][Full Text] [Related]  

  • 27. miRNA-26a expression influences the therapy response to carmustine wafer implantation in patients with glioblastoma multiforme.
    Sippl C; Ketter R; Braun L; Teping F; Schoeneberger L; Kim YJ; List M; Nakhoda A; Wemmert S; Oertel J; Urbschat S
    Acta Neurochir (Wien); 2019 Nov; 161(11):2299-2309. PubMed ID: 31478117
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pattern of recurrence following local chemotherapy with biodegradable carmustine (BCNU) implants in patients with glioblastoma.
    Giese A; Kucinski T; Knopp U; Goldbrunner R; Hamel W; Mehdorn HM; Tonn JC; Hilt D; Westphal M
    J Neurooncol; 2004 Feb; 66(3):351-60. PubMed ID: 15015668
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of carmustine wafers in the treatment of glioblastoma multiforme: a systematic review.
    Zhang YD; Dai RY; Chen Z; Zhang YH; He XZ; Zhou J
    Turk Neurosurg; 2014; 24(5):639-45. PubMed ID: 25269031
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Opening the ventricle during surgery diminishes survival among patients with newly diagnosed glioblastoma treated with carmustine wafers: a multi-center retrospective study.
    Sonoda Y; Shibahara I; Matsuda KI; Saito R; Kawataki T; Oda M; Sato Y; Sadahiro H; Nomura S; Sasajima T; Beppu T; Kanamori M; Sakurada K; Kumabe T; Tominaga T; Kinouchi H; Shimizu H; Ogasawara K; Suzuki M
    J Neurooncol; 2017 Aug; 134(1):83-88. PubMed ID: 28534151
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Occlusion of surgical opening of the ventricular system with fibrinogen-coated collagen fleece: a case collection study.
    Bock HC; Cohnen J; Keric N; Kantelhardt SR; Giese A
    Acta Neurochir (Wien); 2011 Mar; 153(3):533-9. PubMed ID: 21210161
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and Effectiveness of Bis-Chloroethylnitrosourea Wafer Chemotherapy in Elderly Patients with Recurrent Glioblastoma.
    Klein J; Juratli TA; Radev Y; Daubner D; Soucek S; Schackert G; Krex D
    Oncology; 2017; 93(1):43-50. PubMed ID: 28395288
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term follow-up after BCNU wafer implantation in patients with newly diagnosed glioblastoma.
    Shibahara I; Miyasaka K; Sekiguchi A; Ishiyama H; Inukai M; Yasui Y; Watanabe T; Sato S; Hide T; Kumabe T
    J Clin Neurosci; 2021 Apr; 86():202-210. PubMed ID: 33775329
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk of surgical site infection in 401 consecutive patients with glioblastoma with and without carmustine wafer implantation.
    Chaichana KL; Kone L; Bettegowda C; Weingart JD; Olivi A; Lim M; Quinones-Hinojosa A; Gallia GL; Brem H
    Neurol Res; 2015 Aug; 37(8):717-26. PubMed ID: 25916669
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Surgical outcomes for older patients with glioblastoma multiforme: preoperative factors associated with decreased survival. Clinical article.
    Chaichana KL; Chaichana KK; Olivi A; Weingart JD; Bennett R; Brem H; Quiñones-Hinojosa A
    J Neurosurg; 2011 Mar; 114(3):587-94. PubMed ID: 20887095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and efficacy of permanent iodine-125 seed implants and carmustine wafers in patients with recurrent glioblastoma multiforme.
    Darakchiev BJ; Albright RE; Breneman JC; Warnick RE
    J Neurosurg; 2008 Feb; 108(2):236-42. PubMed ID: 18240917
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of Gliadel wafers in the treatment of newly diagnosed GBM: a meta-analysis.
    Xing WK; Shao C; Qi ZY; Yang C; Wang Z
    Drug Des Devel Ther; 2015; 9():3341-8. PubMed ID: 26170620
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of serial changes on computed tomography and magnetic resonance imaging after implantation of carmustine wafers in patients with malignant gliomas for differential diagnosis of tumor recurrence.
    Ohue S; Kohno S; Inoue A; Yamashita D; Suehiro S; Seno T; Kumon Y; Kikuchi K; Ohnishi T
    J Neurooncol; 2016 Jan; 126(1):119-126. PubMed ID: 26384812
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol.
    Souhami L; Seiferheld W; Brachman D; Podgorsak EB; Werner-Wasik M; Lustig R; Schultz CJ; Sause W; Okunieff P; Buckner J; Zamorano L; Mehta MP; Curran WJ
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):853-60. PubMed ID: 15465203
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and feasibility of the adjunct of local chemotherapy with biodegradable carmustine (BCNU) wafers to the standard multimodal approach to high grade gliomas at first diagnosis.
    Salvati M; D'elia A; Frati A; Brogna C; Santoro A; Delfini R
    J Neurosurg Sci; 2011 Mar; 55(1):1-6. PubMed ID: 21464805
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.